On the inoculation category of type a H 1N 1

At the recent media briefing on influenza prevention and control held by the Ministry of Health and the China Center for Disease Control and Prevention, the reporter interviewed Zhao Kai, academician of China Academy of Engineering and head of the vaccine group of the National Expert Committee of the Joint Prevention and Control Mechanism of Influenza A (H 1N 1), aiming at several influenza A vaccines that the public is most concerned about.

Reporter: What are the types of influenza A vaccines in China?

Zhao Kai: China is the first country in the world to approve the marketing of influenza A vaccine. At present, the A-H 1N 1 vaccine approved by the State Food and Drug Administration of the United States is in the form of 15 microgram adjuvant-free split vaccine injection. Up to now, the vaccines approved for marketing are produced by the following eight enterprises: Beijing Kexing Biological Products Co., Ltd., Hualan Biological Vaccine Co., Ltd., Changchun Changsheng Biotechnology Co., Ltd., Shanghai Institute of Biological Products, Beijing Tiantan Biological Products Co., Ltd., Jiangsu Shen Yan Biotechnology Co., Ltd., Zhejiang Tianyuan Biological Pharmaceutical Co., Ltd., Changchun Biological Products Research Institute, etc. Domestic influenza A vaccine adopts influenza A virus strain recommended by the World Health Organization. The production process of the vaccine is basically the same as that of seasonal influenza vaccine in previous years, and it needs to be made after chicken embryo culture, virus inactivation, purification and cracking.